MHRA Deferral Delays Traws Pharma Phase 2a Influenza Study, Backup Candidates Proceed
TRAW•The MHRA has deferred Traws Pharma’s Phase 2a human influenza challenge study for tivoxavir marboxil following a negative regulatory review. The company will advance backup long-acting antiviral candidates and maintains funding into Q1 2027 while preserving TXM’s pharmacokinetic profile.
1. Regulatory Setback
The MHRA’s negative review has postponed the planned Phase 2a human influenza challenge study for tivoxavir marboxil, deferring clinical assessment despite potent efficacy in three animal models of highly pathogenic avian influenza.
2. Advancement of Backup Candidates
Traws Pharma will leverage its portfolio of backup long-acting influenza antivirals, advancing candidates that replicate TXM’s extended pharmacokinetic profile and antiviral potency while excluding any mutagenic potential.
3. Cash Runway and Financial Position
With a cash runway extending into Q1 2027, the company retains sufficient funding to drive alternative influenza antiviral programs and navigate additional regulatory interactions.
